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ABSTRACT
Aims/Introduction: According to some authors, in type 2 diabetes there is a reduced
postprandial action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotro-
pic polypeptide (GIP). However, little is known about the role of fasting incretins in
glucose homeostasis. Our aim was to evaluate, through a two-step cluster analysis, the
possibility of phenotyping patients with type 2 diabetes at onset on the basis of fasting
GLP-1, GIP and ghrelin.
Materials and Methods: A total of 96 patients with type 2 diabetes within 6 months
of onset (mean age 62.40 – 6.36 years) were cross-sectionally studied. Clinical, anthropo-
metric and metabolic parameters were evaluated. At fasting the following were carried
out: assay of GLP-1, GIP, ghrelin, insulin, C-peptide, glucagon and a panel of adipocytoki-
nes (visfatin, resistin, leptin, soluble leptin receptor and adiponectin).
Results: The analysis resulted in two clusters: cluster 1 (63 patients) had significantly
lower levels of GLP-1 (4.93 – 0.98 vs 7.81 – 1.98 pmol/L; P < 0.001), GIP (12.73 – 9.44 vs
23.88 – 28.56 pmol/L; P < 0.001) and ghrelin (26.54 – 2.94 vs 39.47 – 9.84 pmol/L;
P < 0.001) compared with cluster 2 (33 patients). Between the two clusters, no differences
in age, duration of disease, sex, clinical-anthropometric parameters, insulin sensitivity and
adipocytokines were highlighted. However, cluster 1 was associated with significantly
higher levels of glycated hemoglobin (7.4 – 0.61 vs 6.68 – 0.57%, P = 0.007), glucagon
(232.02 – 37.27 vs 183.33 – 97.29 ng/L; P = 0.001), fasting glucose (7.85 – 1.60 vs
6.93 – 1.01 mmol/L; P = 0.003) and significantly lower levels of C-peptide (0.12 – 0.11 vs
0.20 – 0.20 nmol/L; P = 0.017).
Conclusions: The present study suggests that fasting incretins play an important role
in the pathophysiology of type 2 diabetes, which requires to further investigation.
INTRODUCTION
It is known that in normal subjects, oral glucose administration
elicits a higher insulin response than intravenous glucose load
at identical plasma glucose concentrations; this phenomenon,
the incretin effect, is mainly attributed to the postprandial
action of glucagon-like peptide-1 (GLP-1) and glucose-depen-
dent insulinotropic polypeptide (GIP)1–4. However, in recent
years, it has been debated whether post-load GLP-1 and
GIP secretion really are lower in patients with type 2 diabetes
mellitus compared with matched healthy controls5,6. A recent
meta-analysis suggested that patients with type 2 diabetes, in
general, do not show reduced GLP-1 secretion in response to
an oral glucose tolerance test or meal test, and that it is the
deterioration of glycemic control that is associated with reduced
GLP-1 secretion7.
Furthermore, in addition to GLP-1 and GIP, another
incretin, ghrelin, produced in the gastrointestinal tract,
though not involved in the postprandial incretin effect
described, plays an important role in glucose homeostasis8.
The ghrelin effect on plasma insulin and glucose levels in
humans, which is produced mainly in the fasting state, isReceived 26 February 2015; revised 15 June 2015; accepted 9 July 2015
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still a matter of debate. Some groups have found no
changes9–11, whereas others have found increased fasting
blood glucose and decreased plasma insulin after administra-
tion of ghrelin12.
To date, there is a great deal of literature, although con-
troversial, on the postprandial incretin effect and its role in
the pathogenesis of type 2 diabetes; conversely, little is
known about the role of fasting incretin tone, and especially
about the impact of this on the pathophysiology of type 2
diabetes.
In the present study, through a two-step cluster analysis we
evaluated the possibility of phenotyping patients with type 2
diabetes at onset on the basis of fasting serum levels of GLP-1,
GIP and ghrelin.
MATERIALS AND METHODS
A total of 96 consecutive Caucasian patients with type 2
diabetes within 6 months of onset (mean age
62.40 – 6.36 years, range 51–75 years), followed up in our
dedicated outpatients clinic at Unit of Endocrinology, Dia-
betology and Metabolism, University of Palermo, Palermo,
Italy (from 1 March 2012 to 31 December 2013), were
cross-sectionally studied. Inclusion criteria were type 2 dia-
betes known for <6 months and in stable treatment for the
last 3 months with metformin (1.5–2 g/day). Patients with
glycated hemoglobin (HbA1c) ≥8 (64 mmol/mol) were
excluded, in order to avoid the effects of severe glucotoxicity
on incretins and adipocytokines. The following were
excluded: patients with type 1 diabetes and patients with pre-
vious treatment with other antidiabetic drugs taken in the
past 6 months. To avoid interfering with the Visceral Adi-
posity Index, patients with morbid obesity, pendulous abdo-
men, severe hypertriglyceridemia and/or or use of ﬁbrates
were excluded13,14. Patients with macro- or microvascular
complications were excluded (except 8 patients with simple
preproliferative retinopathy). Patients were not excluded if
they had essential hypertension (62 patients). A complete
medical history, a complete physical examination, bodyweight,
height, and waist and hip circumference were recorded for
the patients included. Waist circumference (WC) was mea-
sured midway between the inferior margin of the last rib
and the crest of the ilium in a horizontal plane by the mea-
surer sitting by the subject and ﬁtting the tape snugly, but
not compressing soft tissues. Hip circumference (HP) was
measured around the pelvis at the point of maximal protru-
sion of the buttocks. Fasting blood samples and a morning
spot urine sample were collected for biochemical analyses.
All participants were instructed to carry out home glucose
monitoring (one full-day glucose proﬁle per week: fasting,
2 h after breakfast, 2 h after lunch and 2 h after dinner).
The study was approved by the institutional review board at
the Faculty of Medicine of the University of Palermo. At the
time of observation, all patients regularly signed an informed
consent for scientiﬁc use of their data.
Anthropometric Indices
Body mass index (BMI) was calculated as bodyweight (in
kilograms) divided by the square of height (in meters). Waist-
to-hip ratio was calculated by dividing the waist circumference
by the hip circumference. The Body Adiposity Index (BAI) was
calculated using the following formula15:
BAI ¼ ðððHCÞ=ðheightÞÞ  1:5Þ  1:8
Hip circumference (HC) is expressed in centimeters and
height in meters.
The Visceral Adiposity Index (VAI) was calculated as
described13,14 using the following sex-speciﬁc equation, where
triglyceride (TG) levels are expressed in mmol/L and high-den-
sity lipoprotein (HDL) cholesterol levels expressed are mmol/L:
Females:
VAI ¼ WC
36:58þ 1:89 BMIð Þ
 
 TG
0:81
 
 1:52
HDL
 
Males:
VAI ¼ WC
39:68þ 1:88 BMIð Þ
 
 TG
1:03
 
 1:31
HDL
 
Secretory Units of Islets in Transplantation
As a measure of b-cell function, the secretory units of islets in
transplantation (SUIT)16 were calculated from the fasting
plasma glucose (mg/dL) and fasting C-peptide (ng/mL) levels
using the formula:
ð1485 fasting C-peptideÞ=ðfasting glucose 61:8Þ
Assay
The BioPlex Pro Human Diabetes 10-plex assay (BioRad,
Milan, Italy) was used to quantitate the following diabetes-
related analytes: C-peptide (nmol/L), ghrelin (pg/mL), total
GLP-1 (pmol/L), total GIP (pmol/L), leptin (ng/mL), resistin
(ng/mL) and visfatin (pg/mL). The BioPlex Pro Human Dia-
betes Adipsin and Adiponectin duplex assay (BioRad) was used
for adipsin (ng/mL) and adiponectin (lg/mL) assays. The intra-
and interassay coefﬁcients of variability were 4% and 2% for
ghrelin, 3% and 4% for GIP, and 6% and 3% for GLP-1,
respectively.
All these assays were run on a BioPlex 200 workstation
(BioRad). Human soluble leptin receptor (sOb-R; ng/mL) was
assayed using an enzyme-linked immunosorbent assay sand-
wich enzyme immunoassay (Human leptin receptor ELISA;
BioVendor, Heidelberg, Germany). Serum non-esteriﬁed fatty
acids (mmol/L) were assayed after overnight fasting using an
enzymatic colorimetric method (Randox NEFA assay FA115;
Randox Laboratories, County Antrim, UK). Blood glucose levels
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(mg/dL) were measured using an electrochemical system
(Glucocard; Menarini Diagnostics, Florence, Italy). Total choles-
terol, HDL cholesterol, triglycerides, and urinary albumin and
creatinine were measured in our laboratory using standard
assays. HbA1c was determined by high-pressure liquid chro-
matography with ion-exchange resin (Bio-Rad D-10 HPLC
analyzer). Low-density lipoprotein cholesterol levels were calcu-
lated with Friedewald’s formula. The conversion factors for the
International System were the following: glucose (mg/dL vs
mmol/L; 90.0555), insulin (mUI/L vs pmol/L; 96.945), total
cholesterol (mg/dL vs mmol/L; 90.0259), visfatin (pg/mL vs
ng/mL; 91000), Ghrelin (pg/mL vs pmol/L; 90.296).
Statistical Analysis
The Statistical Packages for Social Sciences, SPSS version 17 (SPSS,
Chicago, IL, USA), was used for data analysis. Baseline character-
istics were presented as mean – standard deviation for continu-
ous variables; rates and proportions were calculated for
categorical data. Normality of distribution for quantitative
variables was assessed by the Shapiro–Wilk test. Some variables
(leptin, leptin/sOb-R ratio, adiponectin and resistin) did not show
normal distribution, and the natural logarithmic transformed
values of each adipocytokine for statistical analysis were used. Dif-
ferences between the two groups were detected by the unpaired
Student’s t-test for continuous variables (after testing for equality
of variance: Levene test) and by the chi square-test and Fisher’s
exact test (when appropriate) for categorical variables.
In order to identify the phenotypes of type 2 diabetes based on
fasting incretin tone, we carried out a two-step cluster analysis
using log-likelihood distance measures. Cluster analysis, also
called segmentation analysis, is an explorative analysis that tries
to identify structures within the data. More speciﬁcally, it tries to
identify homogenous groups of cases based on the distribution of
some variables (input variables). Cluster analysis is used to
identify groups of cases if the grouping is not previously known.
In particular, a two-step cluster analysis is more of a tool than a
single analysis. It identiﬁes the groupings by running pre-cluster-
ing ﬁrst and then by hierarchical methods. In this respect, it
combines the best of both approaches. This technique can detect
latent relationships within a complex dataset between patients
with multiple distinct characteristics. Cluster analysis was applied
using an a priori number of ﬁxed clusters (cluster 1 and
cluster 2), and the three following continuous variables were
included in the analysis (input variables): fasting GLP-1, GIP and
ghrelin. The three variables included produced a silhouette coefﬁ-
cient >0.5, indicative of good data partitioning (Figure 1a). In this
model, the most important variables in the creation of the two
clusters were GLP-1 and GIP (Figure 1a).
For comparison between cluster 1 and cluster 2, the
group sizes gave 74.7% power to detect a moderate effect size
(Cohen’s d = 0.5) using unpaired t-test, with alpha at 0.05.
Post-hoc power analysis was carried out using G*POWER Version
3.1.6 software (Heinrich-Heine-Universit€at D€usseldorf, D€ussel-
dorf, Germany). A P-value of <0.05 was considered statistically
signiﬁcant.
RESULTS
The 96 patients studied were 51 women and 45 men; the clini-
cal characteristics, and the incretin and adipocytokine patterns
of the patients are summarized in Table 1.
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Figure 1 | (a) Model summary of the two-step cluster analysis with a graph of the quality of clusters and importance of the three input variables.
(b) Differences in serum levels of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and ghrelin between
cluster 1 and cluster 2; the ends of the whiskers represent the 5th and 95th percentiles.
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The two clusters derived from the cluster analysis showed
the following fasting incretin patterns: compared with cluster 2
(33 patients), cluster 1 (63 patients) showed signiﬁcantly lower
levels of GLP-1 (4.93 – 0.98 vs 7.81 – 1.98 pmol/L; P < 0.001),
GIP (12.73 – 9.44 vs 23.88 – 28.56 pmol/L; P < 0.001) and
ghrelin (26.54 – 2.94 vs 39.47 – 9.84 pmol/L; P < 0.001; Fig-
ure 1b).
Regarding the clinical and anamnestic characteristics of the
patients, we did not ﬁnd any signiﬁcant differences between the
two clusters, except for a greater prevalence of patients practic-
ing physical activity in cluster 2 (27.3 vs 11.1%; P = 0.044;
Table 2). Similarly, no signiﬁcant differences in anthropometric
parameters were found (Table 2).
Cluster 1 showed a worse glyco-metabolic proﬁle compared
with cluster 2: higher levels of HbA1c (7.41 – 0.61 vs
6.68 – 0.57%; P = 0.007) and fasting plasma glucose
(7.85 – 1.60 vs 6.93 – 1.01 mmol/L; P = 0.003) were found; no
difference was found between the two clusters in regard to
postprandial glucose levels. Regarding pancreatic function, clus-
ter 1 showed signiﬁcantly higher levels of fasting ﬂucagon
(232.02 – 37.27 vs 183.33 – 97.29 ng/L; P = 0.001), lower
Table 1 | Clinical-anthropometric characteristics, incretin and
adipocytokine patterns in 96 patients with type 2 diabetes
Clinical-anthropometric characteristics n (%)
Women 51 (53.1)
Men 45 (46.9)
Mean – SD
Age (years) 62.40 – 6.36
Duration of disease (months) 4.41 – 1.66
BMI (kg/m2) 29.29 – 4.65
Waist circumference (cm) 102.08 – 11.31
Hip circumference (cm) 107.23 – 10.28
Waist-to-hip ratio 0.95 – 0.08
Body Adiposity Index 33.94 – 6.47
Visceral Adiposity Index 2.28 – 1.33
HbA1c
%
mmol/mol
6.92 – 0.62
52 – 6.80
HOMA-IR 3.08 – 3.22
Fasting insulin (pmol/L) 64.32 – 67.26
Fasting C-peptide (nmol/L) 0.15 – 0.15
Fasting glucagon (ng/L) 215.28 – 68.08
Urinary albumin-to-creatinine ratio (mg/g) 16.69 – 38.10
Fasting lipids
Total cholesterol (mmol/L) 4.58 – 0.85
HDL cholesterol (mmol/L) 1.25 – 0.32
LDL cholesterol (mmol/L) 2.76 – 0.84
Triglycerides (mmol/L) 1.41 – 0.56
NEFA (mmol/L) 0.46 – 0.27
Fasting incretins
GLP-1 (pmol/L) 5.92 – 1.96
GIP (pmol/L) 16.56 – 19.01
Ghrelin (pmol/L) 30.99 – 8.74
Fasting adipocytokines
Leptin (ng/dL) 8.83 – 10.45
sOb-R (ng/mL) 21.70 – 6.56
Leptin/sOb-R ratio 0.55 – 0.88
Adiponectin (lg/mL) 11.75 – 12.94
Visfatin (ng/mL) 0.62 – 0.52
Resistin (ng/mL) 4.01 – 4.68
BMI, body mass index; GIP, glucose-dependent insulinotropic polypep-
tide; GLP-1, glucagon-like peptide-1; HbA1c, glycated hemoglobin; HDL,
high-density lipoprotein; HOMA-IR, homeostatic model addessment of
insulin resistance; LDL, low-density lipoprotein; NEFA, non-esterified fatty
acids; SD, standard deviation; sOB-R, soluble leptin receptor.
Table 2 | Differences in clinical and anthropometric characteristics
between cluster 1 and cluster 2
Cluster 1
n (%)
Cluster 2
n (%)
P
n = 63 n = 33
Clinical characteristics
Sex
Male 30 (47.6) 15 (45.5) 0.840
Female 33 (52.4) 18 (54.5)
Family history of
diabetes
51 (81) 24 (72.7) 0.437
Dietary compliance 43 (68.3) 21 (63.6) 0.819
Physical activity 7 (11.1) 9 (27.3) 0.044
Smoking
Current 10 (15.9) 4 (12.1) 0.845
Former 13 (20.6) 8 (24.2)
Metabolic syndrome* 46 (73) 22 (66.7) 0.516
High blood pressure 42 (66.7) 20 (60.6) 0.555
High triglycerides 20 (31.7) 6 (18.2) 0.155
Low HDL cholesterol 40 (63.5) 21 (63.6) 0.989
Increased WC 41 (65.1) 19 (57.6) 0.471
Mean – SD Mean – SD
Age (years) 61.94 – 6.14 63.27 – 6.78 0.348
Duration of disease
(months)
4.51 – 1.66 4.21 – 1.67 0.413
Anthropometric parameters
BMI (kg/m2) 29.56 – 4.49 28.79 – 4.98 0.461
WC (cm) 103.63 – 10.62 99.12 – 12.13 0.076
Hip circumference
(cm)
107.60 – 9.92 106.54 – 11.05 0.647
Waist-to-hip ratio 0.96 – 0.09 0.93 – 0.08 0.067
Body Adiposity
Index
33.90 – 6.20 34.02 – 7.04 0.931
Visceral Adiposity
Index
2.36 – 1.43 2.12 – 1.12 0.364
Student’s t-test after testing for equality of variance (Levene test).
*According to Adult Treatment Panel (ATP) III criteria. BMI, body mass
index; HDL, high-density lipoprotein; SD, standard deviation; WC, waist
circumference.
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levels of fasting C-peptide (0.12 – 0.11 vs 0.20 – 0.20 nmol/L;
P = 0.017) and secretory units of islets in transplantation
(7.66 – 6.35 vs 16.00 – 16.78; P = 0.001; Table 3).
The lipid pattern appeared comparable between the two clus-
ters. No difference was found between the two clusters in
regard to adipocytokine proﬁle (Table 3).
DISCUSSION
In the present study we showed that it is possible to phenotype
patients with type 2 diabetes at onset based on the values of
fasting GLP-1, GIP and ghrelin; patients with reduced fasting
incretin tone are characterized by worse HbA1c and fasting
glucose, probably secondary to reduced fasting b-cell activity
associated with increased a-cell activity.
Regarding the importance of the three variables in the
process of clusterization, the results of the cluster analysis show
that we should give priority to GLP-1 and GIP. In this connec-
tion, fasting ghrelin, although it proved to be signiﬁcantly lower
in the group with reduced fasting incretin tone, was not
decisive in the formation of the two clusters. At present, the
effects of fasting plasma ghrelin on fasting plasma insulin and
glucose levels in humans are still a matter of debate. Some
authors have found no changes9–11, whereas others have found
that acyl ghrelin increased fasting blood glucose and decreased
plasma insulin after its administration12,17,18. Unfortunately, the
present study is not able to contribute to the clariﬁcation of
these aspects, both because of the slight weight of ghrelin in
the formation of the clusters, and because of the limit of having
assayed total ghrelin and not acyl ghrelin.
Instead, a more important role in glucose homeostasis in
patients with type 2 diabetes seems to be played by fasting
levels of GLP-1 and GIP. It is known that the secretion of
GLP-1 (mainly synthesized by L-cells in the duodenum, and
small and large intestine) in the gastrointestinal tract is inﬂu-
enced by glucose and fatty acids after food ingestion or as a
result of vagus nerve stimulation19. The main GLP-1 action
mechanisms involve stimulating insulin secretion by b-cells
in the islets of Langerhans and inhibiting glucagon secretion by
a-cells; increased insulin secretion is the result of its increased
synthesis20–22. The present study has shown that the basal
secretion of GLP-1 also plays an important role in glucose
homeostasis, although with our data we were not able to show
whether this is the result of secretion by L-cells or of degrada-
tion by dipeptidyl peptidase-4 (DPP-4)23,24. Future studies
evaluating the concentration or enzyme activity of DPP-4 in
patients with type 2 diabetes might be clariﬁers. Analogous con-
siderations must be made for GIP (a peptide secreted by K-cells
in the mucosa of the duodenum, jejunum and the proximal
portion of the ileum) about its incretin activity stimulating food
intake-mediated insulin secretion by b-cells in the islets of
Langerhans24,25. In this case too, although the postprandial
levels of GIP depend on the basic nutrient content of a meal
(higher values are observed after the ingestion of carbohydrates,
compared with proteins)26, regarding the fasting serum levels
we do not know if they are the result of secretion by K-cells or
of degradation by DPP-423.
In the present study, what we believe to be of particular
interest is the similarity between the two groups in regard to
the clinical-anthropometric characteristics and the insulin-sensi-
tivity.
Even adipose tissue function was similar, as shown by the
lack of signiﬁcant differences between the two clusters in
relation to the VAI values, leptin, sOb-R, leptin/sOb-R ratio,
adiponectin, visfatin and resistin. Although today it is known
that adipocytokines form an important part of an ‘adipoinsular
Table 3 | Differences in glycometabolic profiles and adipocytokine
pattern between cluster 1 and cluster 2
Cluster 1 Cluster 2 P
n = 63 n = 33
Mean – SD Mean – SD
Glycometabolic profile
HbA1c (%) 7.41 – 0.61 6.68 – 0.57 0.007
HbA1c (mmol/mol) 57 – 6.7 49 – 6.2 0.007
HOMA-IR 2.94 – 3.08 3.35 – 3.50 0.566
Fasting insulin (pmol/L) 59.07 – 60.32 74.34 – 78.88 0.293
Fasting glucagon (ng/L) 232.02 – 37.27 183.33 – 97.29 0.001
Fasting C-peptide (nmol/L) 0.12 – 0.11 0.20 – 0.20 0.017
Fasting glucose (mmol/L) 7.85 – 1.60 6.93 – 1.01 0.003
SUIT 7.66 – 6.35 16.00 – 16.78 0.001
2 h after breakfast glucose
(mmol/L)
6.96 – 1.69 6.47 – 0.93 0.124
2 h after lunch glucose
(mmol/L)
7.74 – 1.88 7.23 – 1.11 0.133
2 h after dinner glucose
(mmol/L)
7.98 – 2.06 7.33 – 1.48 0.082
Urinary albumin-to-creatinine
ratio (mg/g)
19.18 – 45.61 11.93 – 15.62 0.257
Fasting lipids
Total cholesterol (mmol/L) 4.55 – 0.86 4.65 – 0.84 0.603
HDL cholesterol (mmol/L) 1.24 – 0.30 1.26 – 0.36 0.753
LDL cholesterol (mmol/L) 2.71 – 0.84 2.85 – 0.83 0.445
Triglycerides (mmol/L) 1.45 – 0.58 1.33 – 0.50 0.324
NEFA (mmol/L) 0.50 – 0.29 0.39 – 0.21 0.051
Fasting adipocytokine profile
Leptin (ng/dL)* 9.77 – 9.61 7.03 – 11.84 0.257
sOb-R (ng/mL)* 22.20 – 6.71 20.76 – 6.28 0.077
Leptin/sOb-R ratio* 0.56 – 0.69 0.54 – 1.17 0.928
Adiponectin (lg/mL)* 10.46 – 11.14 14.22 – 15.70 0.953
Visfatin (ng/mL) 0.60 – 0.51 0.64 – 0.55 0.788
Resistin (ng/mL)* 4.28 – 5.05 3.49 – 3.90 0.089
Student’s t-test after testing for equality of variance (Levene test).
*The natural logarithmic transformed (Ln) values were used for the
Student’s t-test. BMI, body mass index; HbA1c, glycated hemoglobin;
HDL, high-density lipoprotein; HOMA-IR, homeostatic model
addessment of insulin resistance; LDL, low-density lipoprotein; NEFA,
non-esterified fatty acids; SD, standard deviation; sOB-R, soluble
leptin receptor; SUIT, secretory units of islets in transplantation.
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axis,’ dysregulation of which could contribute to b-cell failure
and hence to type 2 diabetes27, the present data conﬁrm that
the fasting level of incretin hormones do not inﬂuence this axis;
we still cannot exclude a possible role in postprandial phases.
Indeed, it is known that postprandial GLP-1 ampliﬁes insulin-
mediated glucose uptake in adipocytes27, and this certainly
contributes to normal adipocyte function. The same goes for
GIP, which appears to provide a beneﬁt by not only stimulating
postprandial intestinal glucose transport and releasing insulin to
facilitate nutrient storage, but also through its insulin-
mimetic properties, including enhanced uptake of glucose by
adipocytes28.
In conclusion, although the physiological importance of the
decreased fasting level of incretins in patients with type 2 dia-
betes requires further clariﬁcation, the present study suggests
that a simple phenotyping of patients at onset is possible based
on these parameters. In the future, similar studies of larger size
could also suggest the appropriate cut-off of GLP-1 and GIP
pointing to reduced incretin tone, in order to better
select patients who require treatment with GLP-1 analogs or
DPP4-inhibitors.
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